The Evolving Landscape of Behavioral Health Transactions: Insights from Industry Professionals
Private Equity Investment in Long-Term Care – Assisted Living and the Law Podcast
New State Legislation Increases Oversight of Health Care Transactions - Thought Leaders in Health Law®
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 205: Novant Health’s Carolinas Expansion with Senior Vice President Jason Bernd
Current Executive Compensation Trends in Private Equity Transactions — Troutman Pepper Podcast
Navigating the Labyrinth of Private Equity Investments in Health Care – Diagnosing Health Care
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 187: South Carolina Hospitals and Healthcare Industry Trends with Thornton Kirby, SCHA President
Public M&A Day in Frankfurt
Business Better Podcast Episode: Strategic Partnership and Company-Building Investments – A Conversation with Prairie Capital
JONES DAY TALKS®: Corporate Venture Capital: Market Overview, Trends in Deal Terms, and Special Considerations
Business Better Podcast Episode: Investing in the New Mainstream Economy - A Conversation with Palladium Equity Partners
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 170: Joel Gates, Senior Director of Operations for Azzur Cleanrooms on Demand
Business Better Podcast Episode: Investing in Consumer Brands – A Conversation with SBJ Capital
Business Better Podcast Episode: Supporting Middle Market Manufacturing – A Conversation with Torque Capital Group
New SEC Private Funds Rules – What Is Happening and What You Need to Know - Troutman Pepper Podcast
Podcast - Counsel That Cares - Increased Investor Interest in Cardiology
What Physicians Should Know Before Selling Their Medical Practice
Private Equity VS Real Estate Transactions | #6 What’s the Best Order to Sell?
Private Equity VS Real Estate Transactions | #5 Setting Your Rent as Part of a PE Deal
Private Equity VS Real Estate Transactions | #4 Optimizing Total Asset Value
Credit Conditions | Q1 2024: High interest rates in 2023 posed significant challenges for dealmakers and debt markets. However, 2024 brings optimism with anticipated rate cuts and improving market conditions, leading to a...more
82% of respondents expect secondaries activity levels to remain buoyant or increase in the next two years following 4x growth in the past five years. The slowdown in exits and fundraisings seen over the last year is...more
Aggregate global M&A deal value is up significantly in 2024 (even though deal volume is down), driven in large part by the announcement of megadeals in the U.S., and reflecting an appetite for dealmaking in the medium term....more
Latham hosted our second Public M&A Day in Frankfurt, bringing together senior executives and Latham partners to discuss opportunities in the current public M&A sector. Renowned experts and prominent keynote speakers...more
Higher interest rates presented a challenging environment for dealmakers and the debt markets in 2023. But what does 2024 have in store? In this edition of Credit Conditions, we look back at last year’s key market trends and...more
Robust supply chains are vital to our closely connected global economy. Yet escalating geopolitical tensions, persistent inflation and a fragile macroeconomic outlook are presenting businesses with a fresh wave of supply...more
The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Traditional debt financing was expensive and scarce, expectations on valuations were tricky to...more
Ankura is pleased to present an overview of healthcare transactions announced or closed during Q3 2023 in the United States. Total transactions decreased by 13.7% in the third quarter of 2023 after increasing by 4.9% in the...more
Key Points - - New draft merger guidelines reflect the aggressive approach that has defined merger enforcement in the Biden administration, including novel theories of harm. - Proposed changes to HSR notification will make...more
Whole-business securitization (WBS), a structured finance product where a company issues secured debt against substantially all of its cash-yielding assets, is now on the radar of dealmakers seeking ways to manage M&A...more
M&A is proving popular with companies looking to reinvigorate their portfolios and adapt to shifting consumer demands - The North American food sector is experiencing a period of transition. Large food producers benefited...more
The healthcare M&A market appears to be steadying. Although deal activity through the year appears slightly below the high-water marks for the corresponding period of 2022, deal activity is generally up from the first quarter...more
Following a period of rapid growth, the fund finance market has reached an inflection point. Once considered a small, esoteric area of the lending landscape, fund finance—loan facilities secured against investor commitments...more
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
M&A started strong in 2022 with robust deal activity and megadeals dominating the landscape that was largely the result of unprecedented spillover from 2021. But then, things took a turn and deals stalled in the second half...more
In 2022, many predicted we would see a spike in M&A due to the economic downturn and the steep drop in startup valuations. However, last year was not the M&A blockbuster that was predicted, and we even saw a drop-off in...more
As predicted in our previous M&A report, 2022 has not lived up to the runaway performance of 2021. As activity—still at impressive levels considering everything that has been thrown at the deal market—takes a breather, we...more
Explore the data The headline for the first half of 2022 is that US M&A markets are still remarkably healthy, despite a confluence of headwinds. Without question, 2021 was an exceptional year, fueled by pent-up demand,...more
In line with the broader M&A market, private equity firms had an exceptionally busy 2021. Deal value soared to US$987.6 billion in the year, more than doubling what was an already high total of US$474.5 billion in 2020. This...more
Five factors that will shape dealmaking over the coming 12 months - Last year will be a very tough act to follow. M&A values and volumes soared on the back of confident public markets, strong deal financing options and a...more
Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity - Healthcare and pharmaceutical deals continued at a robust pace through 2021, registering the...more
Canadian dealmakers are betting on large overseas purchases as market confidence returns - Canadian dealmakers have become a major presence beyond their borders, conducting a total of 361 outbound deals worth a total of...more
High-growth industries continue to attract investor interest despite COVID disruptions - Vietnam’s M&A activity is set for another robust year following 2020’s potent performance. In the first three quarters, deals with...more
An increase in megadeals reveals growing dealmaker appetite within Italy’s M&A market - Dealmaking confidence appears to be returning within the Italian M&A market. A total of US$57.4 billion-worth of deals announced in...more
The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more